ANNOVIS BIO (ANVS) Stock Price, Forecast & Analysis
USA - NYSE:ANVS - US03615A1088 - Common Stock
ANVS Key Statistics, Chart & Performance
The current stock price of ANVS is 2.1 USD. In the past month the price decreased by -5.41%. In the past year, price decreased by -76.9%.
ANVS Latest News, Press Relases and Analysis
ANVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About ANVS
Company Profile
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Company Info
ANNOVIS BIO
101 Lindenwood Drive, Suite 225
Malvern PENNSYLVANIA 19312 US
CEO: Maria Maccecchini
Employees: 8
Phone: 14848753192
ANNOVIS BIO / ANVS FAQ
Can you describe the business of ANNOVIS BIO?
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Can you provide the latest stock price for ANNOVIS BIO?
The current stock price of ANVS is 2.1 USD. The price increased by 0.96% in the last trading session.
Does ANVS stock pay dividends?
ANVS does not pay a dividend.
What is the ChartMill rating of ANNOVIS BIO stock?
ANVS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting ANVS stock to perform?
11 analysts have analysed ANVS and the average price target is 14.03 USD. This implies a price increase of 567.86% is expected in the next year compared to the current price of 2.1.
How is the valuation of ANNOVIS BIO (ANVS) based on its PE ratio?
ANNOVIS BIO (ANVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
ANVS Technical Analysis
ANVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANVS. ANVS has a great financial health rating, but its profitability evaluates not so good.
ANVS Financial Highlights
Over the last trailing twelve months ANVS reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 52.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -141.04% | ||
| ROE | -165.08% | ||
| Debt/Equity | 0 |
ANVS Forecast & Estimates
11 analysts have analysed ANVS and the average price target is 14.03 USD. This implies a price increase of 567.86% is expected in the next year compared to the current price of 2.1.